Literature DB >> 17064362

Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.

Giuseppe Battaglia1, Maria Grazia Farrace, Pier Giorgio Mastroberardino, Irene Viti, Gian Maria Fimia, Jozef Van Beeumen, Bart Devreese, Gennaro Melino, Gemma Molinaro, Carla Letizia Busceti, Francesca Biagioni, Ferdinando Nicoletti, Mauro Piacentini.   

Abstract

Transglutaminase 2 (TG2) represents the most ubiquitous isoform belonging to the TG family, and has been implicated in the pathophysiology of basal ganglia disorders, such as Parkinson's disease and Huntington's disease. We show that ablation of TG2 in knockout mice causes a reduced activity of mitochondrial complex I associated with an increased activity of complex II in the whole forebrain and striatum. Interestingly, TG2-/- mice were protected against nigrostriatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which is converted in vivo into the mitochondrial complex I inhibitor, 1-methyl-4-phenyl-pyridinium ion. In contrast, TG2-/- mice were more vulnerable to nigrostriatal damage induced by methamphetamine or by the complex II inhibitor, 3-nitropropionic acid. Proteomic analysis showed that proteins involved in the mitochondrial respiratory chain, such as prohibitin and the beta-chain of ATP synthase, are substrates for TG2. These data suggest that TG2 is involved in the regulation of the respiratory chain both in physiology and pathology, contributing to set the threshold for neuronal damage in extrapyramidal disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17064362     DOI: 10.1111/j.1471-4159.2006.04140.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  19 in total

1.  Transglutaminase 2 ablation leads to mitophagy impairment associated with a metabolic shift towards aerobic glycolysis.

Authors:  F Rossin; M D'Eletto; L Falasca; S Sepe; S Cocco; G M Fimia; M Campanella; P G Mastroberardino; M G Farrace; M Piacentini
Journal:  Cell Death Differ       Date:  2014-07-25       Impact factor: 15.828

2.  Transglutaminase 2 inhibits apoptosis induced by calcium- overload through down-regulation of Bax.

Authors:  Sung-Yup Cho; Jin-Haeng Lee; Han-Dong Bae; Eui Man Jeong; Gi-Yong Jang; Chai-Wan Kim; Dong-Myung Shin; Ju-Hong Jeon; In-Gyu Kim
Journal:  Exp Mol Med       Date:  2010-09-30       Impact factor: 8.718

Review 3.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 4.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

Review 5.  Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.

Authors:  Dong Wang; Redouane Tabti; Sabria Elderwish; Hussein Abou-Hamdan; Amel Djehal; Peng Yu; Hajime Yurugi; Krishnaraj Rajalingam; Canan G Nebigil; Laurent Désaubry
Journal:  Cell Mol Life Sci       Date:  2020-02-15       Impact factor: 9.261

6.  Tissue Transglutaminase Knock-Out Preadipocytes and Beige Cells of Epididymal Fat Origin Possess Decreased Mitochondrial Functions Required for Thermogenesis.

Authors:  Kinga Lénárt; Csaba Bankó; Gyula Ujlaki; Szilárd Póliska; Gréta Kis; Éva Csősz; Miklós Antal; Zsolt Bacso; Péter Bai; László Fésüs; András Mádi
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

Review 7.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

8.  Involvement of transglutaminase 2 and voltage-gated potassium channels in cystamine vasodilatation in rat mesenteric small arteries.

Authors:  Morten Engholm; Estéfano Pinilla; Susie Mogensen; Vladimir Matchkov; Elise Røge Hedegaard; Hua Chen; Michael J Mulvany; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2016-01-27       Impact factor: 8.739

Review 9.  Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.

Authors:  P G Mastroberardino; M Piacentini
Journal:  J Intern Med       Date:  2010-11       Impact factor: 8.989

10.  Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.

Authors:  Stephen J McConoughey; Manuela Basso; Zoya V Niatsetskaya; Sama F Sleiman; Natalia A Smirnova; Brett C Langley; Lata Mahishi; Arthur J L Cooper; Marc A Antonyak; Rick A Cerione; Bo Li; Anatoly Starkov; Rajnish Kumar Chaturvedi; M Flint Beal; Giovanni Coppola; Daniel H Geschwind; Hoon Ryu; Li Xia; Siiri E Iismaa; Judit Pallos; Ralf Pasternack; Martin Hils; Jing Fan; Lynn A Raymond; J Lawrence Marsh; Leslie M Thompson; Rajiv R Ratan
Journal:  EMBO Mol Med       Date:  2010-09       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.